Janssen Services, LLC
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
72.7%
-13.8% vs industry average
17%
2 trials in Phase 3/4
63%
5 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Undiagnosed Hepatitis C Infection in an Urban Hospital
Role: collaborator
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Role: collaborator
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Role: collaborator
Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Role: collaborator
IBD-OPERA Database, UC Protocol
Role: collaborator
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
Role: collaborator
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Role: collaborator
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
Role: collaborator
Determining the Barriers and Motivations to Clinical Trial Participation
Role: collaborator
Immune Signature of Palmoplantar Pustulosis
Role: collaborator
Intratympanic Injection for Autoimmune Inner Ear Disease
Role: collaborator
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis
Role: collaborator
All 12 trials loaded